Redefining therapeutic success in HIV patients: an expert view.

dc.contributor.authorAntela, Antonio
dc.contributor.authorRivero, Antonio
dc.contributor.authorLlibre, Josep M
dc.contributor.authorMoreno, Santiago
dc.contributor.authorRET Group
dc.date.accessioned2025-01-07T13:27:23Z
dc.date.available2025-01-07T13:27:23Z
dc.date.issued2021
dc.description.abstractThanks to advances in the field over the years, HIV/AIDS has now become a manageable chronic condition. Nevertheless, a new set of HIV-associated complications has emerged, related in part to the accelerated ageing observed in people living with HIV/AIDS, the cumulative toxicities from exposure to antiretroviral drugs over decades and emerging comorbidities. As a result, HIV/AIDS can still have a negative impact on patients' quality of life (QoL). In this scenario, it is reasonable to believe that the concept of therapeutic success, traditionally associated with CD4 cell count restoration and HIV RNA plasma viral load suppression and the absence of drug resistances, needs to be redefined to include other factors that reach beyond antiretroviral efficacy. With this in mind, a group of experts initiated and coordinated the RET Project, and this group, using the available evidence and their clinical experience in the field, has proposed new criteria to redefine treatment success in HIV, arranged into five main concepts: rapid initiation, efficacy, simplicity, safety, and QoL. An extensive review of the literature was performed for each category, and results were discussed by a total of 32 clinicians with experience in HIV/AIDS (4 coordinators + 28 additional experts). This article summarizes the conclusions of these experts and presents the most updated overview on the five topics, along with a discussion of the experts' main concerns, conclusions and/or recommendations on the most controversial issues.
dc.identifier.doi10.1093/jac/dkab168
dc.identifier.essn1460-2091
dc.identifier.pmcPMC8446931
dc.identifier.pmid34077524
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8446931/pdf
dc.identifier.unpaywallURLhttps://academic.oup.com/jac/article-pdf/76/10/2501/40394464/dkab168.pdf
dc.identifier.urihttps://hdl.handle.net/10668/25526
dc.issue.number10
dc.journal.titleThe Journal of antimicrobial chemotherapy
dc.journal.titleabbreviationJ Antimicrob Chemother
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.page.number2501-2518
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.pubmedtypeReview
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.meshAnti-HIV Agents
dc.subject.meshAnti-Retroviral Agents
dc.subject.meshCD4 Lymphocyte Count
dc.subject.meshHIV Infections
dc.subject.meshHumans
dc.subject.meshQuality of Life
dc.subject.meshViral Load
dc.titleRedefining therapeutic success in HIV patients: an expert view.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number76

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8446931.pdf
Size:
457.7 KB
Format:
Adobe Portable Document Format